Opioid Induced Side Effects Treatment Market Growth and Revenue Analysis By leading players like - Shionogi, Cubist Pharmaceuticals, AIKO Biotechnology, SLA Pharma AG

Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body and are well known for the management of acute pain and cancer related pain among patients of all age group.
As per stats published by National Institute on Drug Abuse (NIDA) on February 2017, despite decreased use of cocaine after 2010, deaths related to cocaine overdose increased, this increase was associated with opioids, primarily with synthetic opioids.

Furthermore, according to NIDA, in 2013, the number of prescriptions for opioids was 207 million around the globe with major share accounted by North America and in 2012, around 2.1 million people in the U.S. suffering from disorders related to prescription opioid pain relievers and out of that, around 467,000 people get addicted to heroin. This fact in turn is expected to favor the growth of opioid induced side effects treatment market in the near future.

Request For a Sample Copy of This Research Report: www.coherentmarketinsights.com/insight/request-sample/387

Opioid induced side effects treatment market is expected to gain rise in market revenue in the near future on the basis of the fact that according to United Nations Office on Drugs and Crime (UNODC) in 2010, annual prevalence of opioids was around 0.6-0.8% in the people having age group 15-64 and 0.3-0.5% in the people having age more than 64 years.

Centers for Disease Control and Prevention (CDC) says that in 2015, in U.S. more than 15,000 people died because of overdose of opioids and highest overdose rate observed in the people between age group of 25-54 years. Furthermore, around 2 million people were dependent on prescription opioids in 2014 and prescription opioid receiver for noncancerous pain were 1 in 4 which takes these drugs for addiction. Also, in the U.S. every day, more than 1000 people treated in emergency department due to misuse of prescription opioids.

Increase in prevalence of chronic disease and cancer cases with raised use of prescription based opioids will favor the growth of opioid induced side effects treatment market in the near future
North America accounts for the major market share of opioid induced side effects treatment market, as U.S. is the biggest consumer for prescription based opioids. As per NIDA in 2013, out of the globe U.S. accounted around 100 percent in case of hydrocodone for example – Lortab, Norco and Vicodin, and 81% for oxycodone for example Endocet and Percocet. Also, as per American Society of Addiction Medicine (ASAM), drug overdose is the leading cause of death in U.S. and prescription opioids is the leading factor behind it. In 2015, 12,990 deaths were related with prescription based pain relievers.

The growth in opioid induced side effects treatment market is expected high in North America followed by Europe and APAC region. As per the data published by UNODC in 2012, the APAC and Africa region are the emerging markets for raw opium which could feed to increase opioid consumption and support the growth of opioid induced side effects treatment industry in near the future. Furthermore, only 20% of opioid users received treatment against their drug dependence and treatment demand is growing in Asia and Europe region. The South America has shown negligible growth in demand for treatment against opioid drug dependency.

Some of the key players in the global opioid induced side effects treatment market are Shionogi & Co., Ltd., Cubist Pharmaceuticals, Inc., AIKO Biotechnology, Inc., SLA Pharma AG, Progenics Pharmaceuticals Inc. and AstraZeneca plc.

Download the PDF brochure: www.coherentmarketinsights.com/insight/request-pdf/387

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.